Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [TSID12277]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma when curative surgery or radiotherapy is unsuitable [ID6663]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC